Cargando…
Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?
A small peptide, OP3-4, blocks receptor activator of NF-κB from binding to its ligand, receptor activator of NF-κB ligand (RANKL), and was reported recently to inhibit bone resorption, promote bone formation and protect cartilage in a preclinical rheumatoid arthritis model. The latter effects may re...
Autores principales: | Sims, Natalie A., Romas, Evange |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650503/ https://www.ncbi.nlm.nih.gov/pubmed/26577945 http://dx.doi.org/10.1186/s13075-015-0861-5 |
Ejemplares similares
-
Evaluation of the anti-RANKL monoclonal antibody in rheumatoid arthritis rats
por: Lv, Dawei, et al.
Publicado: (2022) -
Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
por: Garcia-Gomez, Antonio, et al.
Publicado: (2012) -
Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis
por: Kim, Jeong Yeon, et al.
Publicado: (2012) -
Abdominal vagus nerve stimulation alleviates collagen-induced arthritis in rats
por: Payne, Sophie C., et al.
Publicado: (2022) -
Vav1 inhibits RANKL-induced osteoclast differentiation and bone resorption
por: Jang, Jin Sun, et al.
Publicado: (2019)